Calliditas Therapeutics AB (publ) (NASDAQ:CALT) receives a ‘Neutral’ rating from HC Wainwright

HC Wainwright maintained a neutral rating for the stock Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) in a research report sent to investors Tuesday morning, Benzinga reports. The current target price for the company’s stock is $39.00.

Calliditas Therapeutics AB (publ) Price Performance

CALT opened at $37.95 on Tuesday. The company has a quick ratio of 2.62, a current ratio of 2.69 and a debt to equity ratio of 8.46. Calliditas Therapeutics AB has a 12 month low of $15.25 and a 12 month high of $38.32. The stock has a fifty-day moving average of $20.95 and a 200-day moving average of $21.41. The company has a market capitalization of $1.13 billion, a P/E ratio of -20.51 and a beta of 1.50.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) last released its quarterly earnings data on Thursday, May 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.74). Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. The company’s revenue for the quarter was $28.43 million, compared to analyst expectations of $35.78 million. Stock analysts forecast that Calliditas Therapeutics AB will record 0.29 EPS for the current financial year.

Institutional Trading Calliditas Therapeutics AB (publ)

A hedge fund recently bought new shares of Calliditas Therapeutics AB (publ). Optiver Holding BV acquired a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) during the fourth quarter, according to a recent filing with the Securities and Exchange Commission (SEC). The company purchased 980 shares of the company’s stock valued at approximately $25,000. Institutional investors and hedge funds hold 2.83% of the company’s shares.

About Calliditas Therapeutics AB (publ)

(Get the free report)

Calliditas Therapeutics AB (publ), a commercial-stage biopharmaceutical company focused on identifying, developing and commercializing novel therapeutics in orphan drug indications, with a focus on kidney and liver diseases, which have significant unmet medical need in the United States both Europe and Asia.

read more

Get Calliditas Therapeutics AB (publ) news and ratings every day. – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com’s FREE daily email newsletter.